Last €0.20 EUR
Change Today -0.055 / -22.00%
Volume 0.0
C6L On Other Exchanges
As of 3:21 AM 08/27/14 All times are local (Market data is delayed by at least 15 minutes).

cellcura asa (C6L) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/25/13 - €2.00
52 Week Low
10/4/13 - €0.02
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CELLCURA ASA (C6L)

Related News

No related news articles were found.

cellcura asa (C6L) Related Businessweek News

No Related Businessweek News Found

cellcura asa (C6L) Details

CellCura ASA develops and sells equipment and products for use in assisted reproductive technology (ART) and stem cell research applications worldwide. The company offers CellCura ART lab solution, a track and trace system, which keeps track of embryos throughout the in-vitro process at various intervals, as well as provides a record of images, scoring, determinations, environmental conditions, and media and utensils from gamete collection to embryo replacement. It also offers CellCura software solutions, such as Morphology and image capture software that enables the embryologist to document the internal architecture of oocytes and embryos at various stages of their development using measurements and standard scoring parameters; and CellCura Protein Free Media, a culture media, which eliminates the risks of transmission of blood borne diseases. The company is headquartered in Skien, Norway.

2 Employees
Last Reported Date: 05/9/14

cellcura asa (C6L) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: --
Compensation as of Fiscal Year 2013.

cellcura asa (C6L) Key Developments

CellCura ASA Announces Termination of Market Making Agreement with Norne Securities

CellCura ASA announced the market making agreement with Norne Securities has been cancelled, effective from July 10, 2014.

CellCura ASA Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014

CellCura ASA announced unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported total operating income of NOK 607,000 against NOK 1,806,000 a year ago. Operating loss was NOK 2,469,000 against NOK 5,484,000 a year ago. Loss before tax was NOK 3,136,000 against NOK 5,912,000 a year ago. Loss for the period was NOK 3,020,000 against NOK 5,788,000 a year ago. Basic and diluted loss per share was NOK 0.46 against NOK 1.76 a year ago. Net cash flow from operating activities was NOK 814,000 against NOK 3,258,000 a year ago.

CellCura ASA, Q1 2014 Earnings Call, May 30, 2014

CellCura ASA, Q1 2014 Earnings Call, May 30, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
C6L:GR €0.20 EUR -0.055

C6L Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for C6L.
View Industry Companies

Industry Analysis


Industry Average

Valuation C6L Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.1x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELLCURA ASA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at